

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY <i>(Leave blank)</i>		2. REPORT DATE May 2003	3. REPORT TYPE AND DATES COVERED Technical Report	
4. TITLE AND SUBTITLE Influence of Moderate Altitude Residence on Arterial Oxygen Saturation at Higher Altitudes			5. FUNDING NUMBERS	
6. AUTHOR(S) Stephen R. Muza, Paul B. Rock, Michael Zupan, James Miller, William R. Thomas, Allen Cymerman				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Thermal and Mountain Medicine Division U.S. Army Research Institute of Environmental Medicine Natick, MA 01760-5007			8. PERFORMING ORGANIZATION REPORT NUMBER T03-11	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick Frederick, MD 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT <i>(Maximum 200 words)</i> This study compared the distribution of arterial oxygen saturation (SaO ₂) and subjective symptoms to hypoxia in moderate altitude residents (MAR) and low altitude residents (LAR) following rapid ascent to 4,056 m (pressure altitude). Resting ventilatory parameters (open-circuit spirometry) and SaO ₂ (pulse oximetry) were measured in 38 volunteers (25 men, 13 women) residing for >3 months near Colorado Springs, CO (MAR group). These measurements were made at 1,940 m (US Air Force Academy) and after ~1hr at 4,056 m on the summit of Pikes Peak, CO following ascent by car. Resting SaO ₂ was also measured at 610 m elevation intervals during the ascent. The LAR group of 39 volunteers (30 men, 9 women) were exposed to a similar ascent profile in a hypobaric chamber. Results ($\bar{X} \pm S.D.$): At 1,940 m the MAR subjects' PETCO ₂ and SaO ₂ were 33.6 \pm 2.8 mmHg and 94 \pm 1 %, respectively, and decreased (p<0.001) to 32.1 \pm 4.5 mmHg and 86 \pm 2 % at 4,056 m. At 50 m the LAR group PETCO ₂ and SaO ₂ were 38.7 \pm 2.7 mmHg and 98 \pm 1 %, respectively, and decreased (p<0.001) to 36.4 \pm 3.5 mmHg and 82 \pm 5 % at 4,056 m. Above 2,438 m to 4,056 m, the MAR group SaO ₂ was higher (p<0.001) than the LAR group. Only 1 of the MAR subjects, but 9 of the LAR subjects reported symptoms of Acute Mountain Sickness. These results suggest that prolonged residence at ~2,000 m elevation induces a level of ventilatory acclimatization equivalent to residing at 4,056 m for approximately 4 - 9 days.				
14. SUBJECT TERMS hypobaric hypoxia, ventilation, altitude acclimatization, Acute Mountain Sickness			15. NUMBER OF PAGES 21	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT	

USARIEM TECHNICAL REPORT T03-11

**INFLUENCE OF MODERATE ALTITUDE RESIDENCE ON
ARTERIAL OXYGEN SATURATION AT HIGHER ALTITUDES**

Stephen R. Muza
Paul B. Rock
Michael Zupan
James Miller
William R. Thomas
Allen Cymerman

Thermal and Mountain Medicine Division

May 2003

U.S. Army Research Institute of Environmental Medicine
Natick, MA 01760-5007

and

U.S. Air Force Academy
Human Performance Laboratory and Human-Environmental Research Center
USAFA, CO 80840

DISCLAIMER

The investigators have adhered to the policies for protection of human subjects as prescribed in Army Regulation 70-25, and the research was conducted in adherence with the provisions of 45 CFR Part 46

TABLE OF CONTENTS

<u>Section</u>	<u>Page</u>
List of Figures	iv
List of Tables	v
Background	vi
Acknowledgments	vii
Executive Summary.....	1
Introduction	2
Methods	2
Statistical Analysis	5
Results	5
MAR Group Results	5
LAR Group Results.....	8
Comparison Between MAR & LAR	9
Discussion	13
Conclusions	16
References	18

LIST OF FIGURES

Figure		Page
1	Ascent profile for the LAR and MAR group subjects starting from each group's respective residence altitude.	4
2	Frequency distribution histograms of resting SaO ₂ for both MAR and LAR groups at altitudes between 1,940 to 4,056 m.	10
3	Frequency distribution histograms of resting PETCO ₂ for both MAR and LAR groups at their respective residence altitudes and 4,056 m.	11
4	Correlations between residence altitude resting PETCO ₂ and resting PETCO ₂ and SaO ₂ at 4,056 m for all subjects (MAR and LAR groups combined).	12
5	Frequency distribution histogram of AMS-Cerebral scores for both MAR and LAR groups at 4,056 m.	13
6	Comparison of MAR group resting SaO ₂ ($\bar{X} \pm 95\%$ confidence interval) to LAR subjects from two prior ventilatory acclimatization studies at 4,056 m.	15

LIST OF TABLES

Table		Page
1	LAR and MAR subject characteristics.	3
2	Resting ventilatory parameters at residence altitudes and following rapid ascent to high altitude for the LAR and MAR subjects.	6
3	Resting SaO ₂ and HR following rapid ascent to moderate and high altitudes for the LAR and MAR subjects.	6
4	Between-gender comparison of resting ventilatory parameters at residence altitudes and following rapid ascent to high altitude for the LAR and MAR subjects.	7
5	Correlation coefficients (r) between resting PETCO ₂ at residence altitudes and resting PETCO ₂ , PETO ₂ and SaO ₂ at 4,056 m for the LAR and MAR subjects.	7
6	Correlation coefficients (r) between resting SaO ₂ at select altitudes and resting SaO ₂ at higher altitudes for the LAR and MAR subjects.	7
7	The LAR and MAR subjects' symptom scores at 4,056 m altitude following rapid ascent.	8

BACKGROUND

Mountainous terrain provides sanctuary for hostile forces as seen in Central and West Asia, the Balkans, and South America. This harsh environment lessens U.S. military technological superiority by limiting use of air support and crew-served combat vehicles. This places the burden of combat on dismounted warfighters. Objective Force Warrior (OFW) emphasizes the rapid deployment and mobility of troops to conduct operations for sustained periods without relief. However, rapid deployment of unacclimatized troops to high mountainous environments causes debilitating effects on fighting capabilities and Force health. Environmental illnesses are a significant portion of the non-battle injuries sustained by U.S. military forces. For example, during a major combat operation in Afghanistan, ~12% of medevacs and hospital admissions were due to severe Acute Mountain Sickness. Available guidance for minimizing adverse effects of high altitude is based on worst-case scenarios that assume the personnel have no degree of altitude acclimatization. Many military bases are located at altitudes at which personnel will develop some magnitude of altitude acclimatization (>1,500 m). However, the magnitude of altitude acclimatization developed in lowlanders residing at moderate altitudes has not been well documented. This study compared the distribution of arterial oxygen saturation and subjective symptoms to hypoxia in moderate altitude residents and low altitude residents following rapid ascent to 4,056 m (pressure altitude). This work will add to a database that will contribute to the development of models that should provide operational commanders with medical planning capability for high mountainous operations, resulting in decreased altitude illness, and reduced manpower and logistical and medical support requirements.

ACKNOWLEDGMENTS

The authors would like to thank the following individuals for their assistance in conducting this study and preparing this technical report: CPT Tamara M. McReynolds, SGT Dan Ditzler, SGT Tommy Bruington, Janet Staab, Sean Pidgeon, Vinnie Forte, and Karen Speckman.

EXECUTIVE SUMMARY

The magnitude of altitude acclimatization developed in lowlanders residing at moderate elevations (1,000 - 2,000 m) has not been well documented. Moreover, there is no comprehensive database that describes the degree to which acclimatization to moderate altitudes improves arterial oxygenation upon rapid ascent to altitudes above 2,000 m. We propose that lowlanders acclimatized to moderate altitudes will maintain a higher level of arterial oxygenation when rapidly ascending to higher altitudes compared to lowlanders residing at low altitudes.

The purpose of this study was to compare the distribution of arterial oxygen saturation (SaO₂) and subjective symptoms to hypoxia in moderate altitude residents (MAR) and low altitude residents (LAR) following rapid ascent to 4,056 m (pressure altitude). Resting ventilatory parameters (open-circuit spirometry) and SaO₂ (pulse oximetry) were measured in 38 volunteers (25 men, 13 women) residing for >3 months near Colorado Springs, CO (MAR group). These measurements were made at 1,940 m (US Air Force Academy) and after ~1 h at 4,056 m on the summit of Pikes Peak, CO, following ascent by car. Resting SaO₂ was also measured at 610 m elevation intervals during the ascent. The 39 (30 men, 9 women) LAR volunteers were exposed to a similar ascent profile in a hypobaric chamber.

The following results were obtained ($\bar{X} \pm$ S.D.): At 1,940 m the MAR group PETCO₂ and SaO₂ were 33.6 ± 2.8 mmHg and $94 \pm 1\%$, respectively, and decreased ($p < 0.001$) to 32.1 ± 4.5 mmHg and $86 \pm 2\%$ at 4,056 m. At 50 m the LAR group PETCO₂ and SaO₂ were 38.7 ± 2.7 mmHg and $98 \pm 1\%$, respectively, and decreased ($p < 0.001$) to 36.4 ± 3.5 mmHg and $82 \pm 5\%$ at 4,056 m. Above 2,438 m to 4,056 m, the MAR group SaO₂ was higher ($p < 0.001$) than the LAR group. For all subjects, the PETCO₂ at their residence altitudes showed an indirect correlation to PETO₂ and SaO₂ and a direct correlation to PETCO₂ at 4,056 m. Only 1 of the MAR but 9 of the LAR subjects reported symptoms of Acute Mountain Sickness (AMS).

When referenced to published acclimatization data (13,14), our results suggest that prolonged residence at ~2,000 m elevation induces a level of ventilatory acclimatization equivalent to residing at 4,056 m for approximately 5 - 9 days. We speculate that given the degree of ventilatory acclimatization achieved by personnel residing at the moderate altitude studied, we would expect such personnel to be less susceptible to AMS and decrements in cognitive and physical performance during rapid ascent to higher altitudes.

INTRODUCTION

During long-term (days to weeks) exposures to high altitudes, humans compensate for the decreased inspired oxygen partial pressure (PiO_2) by progressively increasing ventilation (for a review, see references (5,25)). For example, following rapid ascent to 4,300 m elevation, ventilation increases during the first 6 - 8 days (14). The rise in ventilation produces a decrease in arterial carbon dioxide partial pressure ($PaCO_2$) and a concomitant increase in PaO_2 (23).

The time course and magnitude for acquiring altitude acclimatization has been well described for unacclimatized lowlanders rapidly ascending to high altitudes. However, the magnitude of altitude acclimatization developed in lowlanders residing at moderate elevations (1,000 - 2,000 m) has not been well documented. Moreover, there is no comprehensive database that describes the degree to which acclimatization to moderate altitudes improves arterial oxygenation upon rapid ascent to altitudes above 2,000 m. We propose that lowlanders acclimatized to moderate altitudes will maintain a higher level of arterial oxygenation when rapidly ascending to higher altitudes compared to lowlanders residing at low altitudes.

Numerous military installations housing large numbers of military personnel are located at moderate altitudes. Development of a database that describes the distribution of arterial oxygen saturation in lowlanders acclimatized to a range of moderate altitudes would provide commanders with ascent timetables to higher elevations that take full advantage of the personnel's acclimatization status. Furthermore, current limits on the time that aircrews of unpressurized aircraft may fly above 3,048 m without supplemental oxygen are based on studies of unacclimatized lowlanders. Altitude-acclimatized aircrews may be able to safely operate beyond these limits, thus enhancing operational capability.

The purpose of this study was to determine the distribution of resting arterial oxygen saturation in personnel residing near sea level or acclimatized to moderate (1,675 - 2,255 m) altitude following rapid ascent to altitudes between 1,940 and 4,056 m. To determine if acclimatization to moderate altitude improves arterial oxygen saturation at higher altitudes, comparisons were made between personnel acclimatized to moderate altitude and unacclimatized subjects.

METHODS

Studies were conducted on 77 military personnel divided into two groups based on their residence altitude (Table 1). The low altitude residents (LAR) resided near sea level (elevation 20 - 100 m) in the Boston, MA, metropolitan area. The LAR group volunteers were military personnel assigned to SSCOM or ARIEM in Natick, MA. The moderate altitude residents (MAR) resided in the Colorado Springs, CO, metropolitan area (elevation ranging from 1,675 - 2,255 m). The MAR group consisted of military personnel assigned to the U.S. Air Force Academy (USFA) or Pederson AFB, CO.

Personnel in each group had resided at their respective elevation for at least 3 months prior to the study. All the subjects had passed their most recent military physical performance test and were in good health. Women volunteers tested negative for pregnancy.

Table 1. LAR and MAR subject characteristics.

Group	N	# males	# females	Age (y)	Height (cm)	Weight (kg)
MAR	38	25	13	34.8 ± 7.8 *	175.5 ± 8.5	74.9 ± 13.8
LAR	39	30	9	26.2 ± 8.8	175.4 ± 9.9	77.5 ± 12.9


$\bar{X} \pm S.D.$ * $p < 0.05$ MAR vs. LAR

The MAR group was studied first. For each subject, all testing was completed on 1 day. On the day of testing, subjects reported to an indoor test site located at the USAFA (Pb 606 ± 1 mmHg, pressure altitude 1,940 m). At that site, several test procedures were performed: administration of an Environmental Background Survey (EBS) and the Environmental Symptoms Questionnaire (ESQ), and measurement of resting ventilatory parameters.

After completion of these procedures, subjects entered a van and were transported to the U.S. Army Pikes Peak Laboratory Facility on the summit (4,300 m terrestrial elevation) of Pikes Peak, CO, via the Pikes Peak Highway. The van stopped at the following pressure altitudes according to the prevailing barometric pressure: 2,438 m (Pb 560 ± 2 mmHg), 3,048 m (Pb 521 ± 1 mmHg), 3,658 m (Pb 484 ± 1 mmHg) and 4,056 m (Pb 459 ± 1 mmHg). At each stop, the subjects remained in the van at rest for approximately 5 min after which their arterial oxygen saturation (SaO₂) and heart rate (HR) were recorded. Upon arriving at the summit, the same 5 min measurements were made after which the subjects entered the U.S. Army Pikes Peak Laboratory Facility. The subject's resting ventilatory parameters were measured within 50 min of arriving on the summit. After about 1 h on the summit, the subjects were administered the ESQ. The subjects then returned to the USAFA and were released from the study. The ascent profile is illustrated in Figure 1.

The LAR group was tested at the USARIEM hypobaric chamber facility, Natick, MA. The same test order and procedures previously performed on the MAR group were followed. Baseline measurements were made at the prevailing barometric pressure (759 ± 8 mmHg). Then the hypobaric chamber was decompressed at 305 m/min to a pressure altitude of 1,940 m (equivalent to the MAR baseline test altitude). After 20 minutes at this altitude, resting SaO₂ and HR were recorded. Then the same average ascent rate to higher altitudes previously obtained during the MAR group tests (Figure 1) was duplicated in the hypobaric chamber.

Figure 1. Ascent profile for the LAR and MAR group subjects starting from each group's respective residence altitude.



At both test sites the following test procedures were performed. Each subject's height and weight were measured. Then each subject completed the EBS. The EBS is a 57-item questionnaire designed to elicit information on test volunteer's previous experience in stressful climatic conditions, participation in physical activities, and medical history. The presence of hypoxic-induced symptoms (dizziness, shortness of breath, alertness, etc) and the incidence of Acute Mountain Sickness (AMS) were determined from information gathered using the ESQ. The ESQ is a self-reported, 67-question inventory used to document symptoms induced by altitude and other stressful environments (19). A weighted average of scores from cerebral symptoms (headache, lightheaded, dizzy, etc.) designated AMS-C and from respiratory symptoms (short-of-breath, hurts-to-breathe, etc.) designated AMS-R were calculated. AMS-C scores greater than 0.7 and AMS-R scores greater than 0.6 are defined as indicating the presence of AMS (19). Also, an alertness factor and fatigue factor were calculated from the questionnaire (19).

Each subject's resting minute ventilation (VE), and end-tidal oxygen and carbon dioxide partial pressure (PETCO₂ and PETO₂) were measured using an open-circuit metabolic measurement system (SensorMedics Vmax229). Simultaneously, SaO₂ and HR were measured by pulse oximetry (Nellcor N-200). The subjects were studied after having fasted for at least 2 h and having been seated at rest for at least 10 min. Resting ventilation was measured once at the subject's residence altitude (1,940 m for the MAR group and 50 m for the LAR group), and once upon arrival on the summit of

Pikes Peak (MAR group) or the same equivalent pressure altitude in the hypobaric chamber (LAR group).

STATISTICAL ANALYSIS

To determine if acclimatization to moderate altitude improves arterial oxygen saturation at higher altitudes, two-way (residence altitude group and altitude exposure) analysis of variance with repeated measures in one factor (altitude exposure) was used to analyze the data. Data that deviated significantly from normality or failed to meet the qualifying assumptions of analysis of variance were analyzed using appropriate non-parametric techniques (i.e., ANOVA on ranks, or Mann-Whitney rank sum test). Possible gender influences were analyzed using the T-test, or if the data deviated significantly from normality or failed to meet the qualifying assumptions of analysis of variance, the data were analyzed using the Mann-Whitney Rank Sum Test. Lastly, potential relationships between measured parameters were tested using the Pearson Product Moment Correlation. Statistical significance was accepted at $p \leq 0.05$. All data are reported as the group mean (\bar{X}) \pm standard deviation (S.D.).

RESULTS

Subject demographics are presented in Table 1. Based on analysis of the EBS, all subjects regularly participated in aerobic physical conditioning and nearly half in strength conditioning. The MAR were significantly older than the LAR.

MAR GROUP RESULTS

Resting ventilatory parameters are listed in Table 2. At the MAR test site, $P_{ET}O_2$, $P_{ET}CO_2$, and SaO_2 were significantly ($p < 0.05$) lower than normal values reported for lowlanders residing near sea level (7). During the approximately 2 h ascent to 4,056 m, resting SaO_2 progressively decreased (Table 3). The decrease in SaO_2 with increasing altitude was significant ($p < 0.001$) at and above the 3,048 m elevation. There was no significant change in resting HR (Table 3) during the ascent to 4,056 m.

Table 2. Resting ventilatory parameters at residence altitudes and following rapid ascent to high altitude for the LAR and MAR subjects.

Group	Altitude (m)	VO ₂ (l/min)	VE (l/min)	PET _O ₂ (mmHg)	PET _{CO} ₂ (mmHg)	SaO ₂ (%)	HR (b/m)
MAR	1,940	0.296 ± 0.051	10.7 ± 2.3	75.4 ± 4.9*	33.6 ± 2.8*	94 ± 1*	71 ± 11
	4,056	0.284 ± 0.053	10.5 ± 2.6	51.5 ± 5.7 [†]	32.1 ± 4.5*	87 ± 3 [†]	68 ± 9
LAR	50	0.222 ± 0.064	10.3 ± 1.8	105.9 ± 3.4	38.7 ± 2.7	98 ± 1	73 ± 10
	4,056	0.249 ± 0.072	12.1 ± 2.5	48.0 ± 4.1 [†]	36.4 ± 3.5 [†]	82 ± 5 [†]	83 ± 13 [†]

$\bar{X} \pm$ S.D. [†] p<0.05 Residence altitude vs. 4,056 m. * p<0.05 MAR vs. LAR

Table 3. Resting SaO₂ and HR following rapid ascent to moderate and high altitudes for the LAR and MAR subjects.

Pressure Altitude (m)	MAR GROUP		LAR GROUP	
	SaO ₂ (%)	HR (b/m)	SaO ₂ (%)	HR (b/m)
1,940	94 ± 1	71 ± 11	96 ± 2	70 ± 8
2,438	94 ± 2	68 ± 9	94 ± 2	73 ± 10
3,048	92 ± 2	68 ± 8	91 ± 2	75 ± 11
3,658	90 ± 2*	68 ± 8*	86 ± 3	78 ± 12
4,056	87 ± 3*	68 ± 9*	82 ± 5	83 ± 13

$\bar{X} \pm$ S.D. * p<0.05 MAR vs. LAR

The SaO₂, PET_O₂ and PET_{CO}₂ decreased significantly between 1,940 m and 4,056 m in all MAR subjects (Table 2), but there was no change in resting metabolic rate (VO₂). The SaO₂ showed an 8% mean decrease between 1,940 m and 4,056 m. The range of SaO₂ at 4,056 m was 83%-93%. At 1,940 m, ventilation in the MAR group females was significantly greater than in the males (Table 4), but there was no significant difference in these values between MAR group males and females at 4,056 m. Interindividual differences in resting SaO₂ at 4,056 m were not related to age, physical fitness, or frequency of trips to altitudes above 1,940 m. For all MAR subjects, the PET_{CO}₂ at their residence altitude (1,940 m) showed an indirect correlation to SaO₂ and a direct correlation to PET_{CO}₂ at 4,056 m (Table 5). Likewise, the MAR subjects resting SaO₂ at 2,438 m was positively correlated with their resting SaO₂ at each higher altitude (Table 6).

Table 4. Between-gender comparison of resting ventilatory parameters at residence altitudes and following rapid ascent to high altitude for the LAR and MAR subjects.

Group	Altitude (m)	Males			Females		
		PETCO ₂ (mmHg)	PETO ₂ (mmHg)	SaO ₂ (%)	PETCO ₂ (mmHg)	PETO ₂ (mmHg)	SaO ₂ (%)
MAR	1,940	34.2 ± 2.8	74.0 ± 4.9	94 ± 1	32.3 ± 2.1 [†]	78.1 ± 3.7 [†]	95 ± 1
	4,056	32.7 ± 4.1	50.9 ± 4.5	86 ± 2	30.9 ± 5.0	52.8 ± 7.6	86 ± 3
LAR	50	39.3 ± 2.6	105.2 ± 3.4	98 ± 1	36.9 ± 2.2 [†]	108.2 ± 2.1 [†]	99 ± 1
	4,056	36.6 ± 3.8	47.5 ± 4.1	82 ± 5	35.8 ± 2.4	49.8 ± 3.5	84 ± 6

$\bar{X} \pm S.D.$ [†] $p < 0.05$ Females vs. Males within MAR and LAR groups.

Table 5. Correlation coefficients (r) between resting PETCO₂ at residence altitudes and resting PETCO₂, PETO₂ and SaO₂ at 4,056 m for the LAR and MAR subjects.

Group	N	4,056 m PETCO ₂		4,056 m PETO ₂		4,056 m SaO ₂	
		r	P	R	P	r	P
MAR	38	0.80	>0.0001	-0.66	>0.0001	-0.42	0.013
LAR	39	0.56	0.0002	-0.40	0.011	-0.23	0.17

Table 6. Correlation coefficients (r) between resting SaO₂ at select altitudes and resting SaO₂ at higher altitudes for the LAR and MAR subjects.

Group	SaO ₂	3,048 m	3,658 m	4,056 m
MAR	2,438 m	0.65*	0.40*	0.30
	3,048 m	-	0.56*	0.51*
	3,658 m		-	0.78*
LAR	2,438 m	0.50*	0.58*	0.36*
	3,048 m	-	0.63*	0.64*
	3,658 m		-	0.54*

* $p < 0.05$

Although there were significant ($p < 0.001$) increases in both AMS-C and AMS-R scores at 4,056 m, only one MAR subject's AMS-C score met the diagnostic criterion for AMS. The mean AMS-C and AMS-R scores were well below the 0.7 and 0.6 threshold criterion for AMS (site article) (Table 7). Compared to 1,940 m, fatigue scores showed a small but significant increase ($p < 0.001$) at 4,056 m. However, alertness was not affected by ascent to 4,056 m.

Table 7. The LAR and MAR subjects' symptom scores at 4,056 m altitude following rapid ascent.

Group	Altitude (m)	AMS-C	AMS-R	Alertness	Fatigue
MAR	1,940	0.020 ± 0.050	0.075 ± 0.105	1.791 ± 0.809	0.165 ± 0.187
	4,056	0.291 ± 0.194 [†]	0.135 ± 0.135 [†]	1.893 ± 0.534	0.502 ± 0.378 [†]
LAR	50	0.014 ± 0.041	0.082 ± 0.104	1.809 ± 0.828	0.215 ± 0.222
	4,056	0.360 ± 0.363 [†]	0.301 ± 0.263 [†]	1.714 ± 0.756	0.703 ± 0.489 ^{†*}

$\bar{X} \pm S.D.$ [†] $p < 0.05$ Residence altitude vs. 4,056 m. ^{*} $p < 0.05$ MAR vs. LAR

LAR GROUP RESULTS


At the LAR test site (50 m), resting SaO_2 , $PETO_2$ and $PETCO_2$ were within the normal range for unacclimatized lowlanders (7). These values decreased significantly during ascent to 4,056 m, but there was no change in resting metabolic rate. Specifically, the decrease in SaO_2 with increasing altitude was significant ($p < 0.001$) at and above 1,940 m elevation. The SaO_2 showed a $16 \pm 5\%$ decrease between 50 m and 4,056 m. The range of SaO_2 at 4,056 m was 74%-96%. At 50 m altitude, ventilation in the LAR group females was significantly greater than in the males (Table 4), but there was no significant difference between males and females SaO_2 at or above 1,940 m, nor $PETCO_2$ or $PETO_2$ at 4,056 m (Table 4). Furthermore, interindividual differences in resting SaO_2 at 4,056 m were not related to age, physical fitness or frequency of trips to higher altitudes. For all LAR subjects, the $PETCO_2$ at their residence altitude (~50 m) showed a direct correlation to $PETCO_2$ at 4,056 m and an indirect correlation to $P_{ET}O_2$ but not SaO_2 at 4,056 m (Table 5). Likewise, the LAR subjects resting SaO_2 at 2,438 m was positively correlated with their resting SaO_2 at each higher altitude (Table 6).

In the LAR group, there were significant ($p < 0.001$) increases in both AMS-C and AMS-R scores at 4,056 m (Table 7). Although the mean AMS-C and AMS-R scores were well below the 0.7 and 0.6 threshold criterion for AMS, the AMS-C scores of 9 subjects in the LAR group met the criteria for diagnosis of AMS. There was no correlation between AMS symptom scores and resting ventilation parameters at 4,056 m. Compared to 50 m, fatigue scores showed a small but significant increase at 4,056 m. However, alertness was not affected by ascent to 4,056 m.

COMPARISON BETWEEN MAR & LAR

At 1,940 m the MAR group $PETO_2$, $PETCO_2$, and SaO_2 were lower ($p < 0.001$) than the sea level values obtained from the LAR subjects (Table 2). After the LAR subjects were decompressed to 1,940 m in the hypobaric chamber, their SaO_2 values were not significantly different from the MAR group at that altitude (Table 3) or at 2,438 m. However, with further ascent above 2,438 m, the MAR group resting SaO_2 was significantly greater than the LAR group resting SaO_2 at all higher altitudes. Ultimately, the mean difference in SaO_2 between the two groups increased to 5% with ascent to 4,056 m. The distribution of resting SaO_2 for both groups at altitudes between 1,940 to 4,056 m is illustrated in Figure 2. In addition to the shift to lower resting SaO_2 in both groups with increasing altitude, these frequency distribution histograms clearly show that the range of resting SaO_2 widened more in the LAR group than in the MAR group at all altitudes.

Figure 2. Frequency distribution histograms of resting SaO₂ for both MAR and LAR groups at altitudes between 1,940 to 4,056 m.



At 4,056 m, the greater ventilation in the MAR group compared to the LAR group is substantiated by the MAR group higher $PETCO_2$ and lower $PETCO_2$ (Table 2). Figure 3 shows the frequency distribution of resting $PETCO_2$ for both groups at their residence altitudes and 4,056 m. At both altitudes, the MAR group range of resting $PETCO_2$ was shifted to lower values relative to the LAR group. When the two groups' resting $PETCO_2$ values were combined, the wide range of individual resting $PETCO_2$ values yield significant direct correlation between residence altitude $PETCO_2$ and their $PETCO_2$ at 4,056 m and an indirect correlation to SaO_2 at 4,056 m (Figure 4).

Figure 3. Frequency distribution histograms of resting $PETCO_2$ for both MAR and LAR groups at their respective residence altitudes and 4,056 m.






Figure 4. Correlations between residence altitude resting PETCO₂ and resting PETCO₂ and SaO₂ at 4,056 m for all subjects (MAR and LAR groups combined).



The mean AMS-C and AMS-R scores at 4,056 m were not significantly different between the MAR and LAR groups (Table 7). However, as noted earlier, 9 LAR subjects but only 1 MAR subject had symptom scores consistent with the presence of AMS. The wider range of AMS-C scores in the LAR group is illustrated in Figure 5. Fatigue scores between the two groups showed a significant ($p=0.049$) difference, with the MAR group having a lower fatigue score. However, there was no difference in alertness scores between the two groups (Table 7).

Figure 5. Frequency distribution histogram of AMS-Cerebral scores for both MAR and LAR groups at 4,056 m.



DISCUSSION

The key findings from this study follow: (1) MAR residing at ~2,000 m for greater than 90 days are mildly hypoxic at their residence altitude, (2) above 2,438 m, the MAR group resting SaO₂ was higher than the LAR group, (3) with increasing altitude, the range of resting SaO₂ widened more in the LAR group than in the MAR group, (4) for all subjects, the PETCO₂ at their residence altitudes showed an indirect correlation to PETO₂ and a direct correlation to PETCO₂ at 4,056 m, and (5) only 1 of the MAR subjects but 9 of the LAR subjects developed AMS during this brief ascent to 4,056 m. These findings are consistent with our hypothesis that lowlanders acclimatized to

moderate altitudes will maintain a higher level of arterial oxygenation when rapidly ascending to higher altitudes compared to lowlanders residing at low altitudes.


On one hand it is not a remarkable finding that individuals acclimatized to moderate high altitude (~2,000 m in this study) sustained a higher level of ventilation than unacclimatized lowlanders. However, this study provides the first quantitative assessment of the degree of ventilatory acclimatization achieved by a fit population residing at moderate altitudes. Thus, this work provides a quantitative basis for developing models and establishing guidelines for protecting Force health and sustaining operational performance during operations in high mountainous terrains.

Given the relatively large sample size used in this study, analysis of the dispersion of the ventilatory parameters measured was possible. The most significant finding was that the unacclimatized LAR subjects demonstrated a wider range of ventilatory responses to increasing high altitudes relative to the acclimatized MAR subjects (Fig. 2). This suggests that altitude acclimatization narrows the interindividual differences within a given population. Review of ventilatory data published from previous studies (13,14) of lowlanders residing for 12 or more days at 4,056 m demonstrate a similar narrowing of the range of ventilatory responses as acclimatization develops. We suspect that this narrowing of interindividual differences is primarily achieved by raising the ventilatory responses of subjects with the smallest ventilatory response to acute hypoxia. The present study suggests that the level of ventilatory acclimatization achieved at moderate altitude was sufficient to narrow the interindividual ventilatory differences at higher altitudes. Thus, moderate altitude residence results in a more uniform level of ventilatory acclimatization within that population.

As noted, previous studies have reported a large variation among individuals in the degree of ventilatory acclimatization at high altitude (20,22). Reeves et al. (14) reported that the variability in the degree of ventilatory acclimatization at high altitude was related to the individual's sea level end-tidal $P_{ET}CO_2$. That is, the lower the individual's $P_{ET}CO_2$ at sea level, the greater their ventilation at high altitude. The current study extends this relationship to subjects residing at moderate altitude (Table 5). This relationship may be potentially useful in predicting an individual's ventilatory response and subsequent well-being to a future high-altitude exposure. However, measurement of $P_{ET}CO_2$ requires sensitive analyzers and respiratory measurement apparatus that do not lend themselves to widespread use. On the other hand, the simple noninvasive and portable measurement of SaO_2 by pulse oximetry may provide a measure of ventilatory acclimatization under the proper circumstances. Because of the shape of the oxyhemoglobin disassociation curve, separation of individuals with wide-ranging degrees of ventilatory acclimatization does not occur until the arterial PO_2 drops below 60 mmHg, or a corresponding SaO_2 of about 92% (10). In the present study, this range of SaO_2 was observed starting at 2,438 m and was very apparent at 3,048 m (Table 6). Thus, measurement of resting SaO_2 at altitudes of 2,438 m or more are predictive of resting SaO_2 at higher altitudes and may be a useful clinical tool for assessing ventilatory acclimatization in a field or operational setting.

This study was designed to make a direct comparison of ventilatory and symptom responses to high altitude between the MAR and LAR groups. What the study did not do was provide a comparison between the MAR group and a LAR group that had achieved full ventilatory acclimatization to 4,056 m. However, numerous studies have reported the ventilatory response on arrival and during residence on the summit of Pikes Peak (3,4,13,14,24). The results of two of these studies (13,14) and our current study are illustrated in Figure 6. When sea level residents rapidly ascend to a pressure altitude of 4,056 m, on arrival their P_{ETCO_2} is 34.9 ± 2.8 mmHg and their SaO_2 is $81 \pm 5\%$. It takes 9 - 12 days of continuous residence at high altitude for the SaO_2 to rise to $88 \pm 2\%$. By comparison, upon rapid ascent to 4,056 m, the MAR subjects' resting SaO_2 was $86 \pm 2\%$. These data suggest that personnel residing at ~2,000 m elevation for more than 90 days have acquired a level of ventilatory acclimatization equivalent to residing at 4,056 m for 5 - 9 days.

Figure 6. Comparison of MAR group resting SaO_2 ($\bar{X} \pm 95\%$ confidence interval) to LAR subjects from two prior ventilatory acclimatization studies at 4,056 m.



In many individuals, the stress of the hypoxic environment causes physiological dysfunctions, which may be manifest in the form of several altitude illnesses including AMS. AMS is a syndrome that is characterized by headache, anorexia, nausea, vomiting, insomnia, lassitude, and malaise (16). The syndrome has great individual variation in susceptibility; however, the hypoxia-induced symptoms are most common in unacclimatized, low-altitude residents who rapidly ascend to terrestrial elevations exceeding 2,500 m. Between 2,000 to 4,000 m, the incidence and severity of AMS in unacclimatized individuals rapidly increases from ~20% to ~70% (16). In addition, the development of AMS appears to be promoted by engaging in physical activities at high altitude. The symptoms of AMS commonly appear within 4 to 24 h of exposure, and usually resolve after several days as acclimatization to hypoxia is achieved. AMS is usually self-limited, but may progress into high altitude cerebral edema (HACE) or high altitude pulmonary edema (HAPE), both of which are potentially life threatening (15).

There is evidence that AMS-susceptible subjects have a relatively greater degree of hypoxemia compared to well subjects at high altitude. Many studies have reported that compared to well subjects, subjects who will develop and who have developed AMS have either a lower alveolar ventilation, alveolar oxygen partial pressure (PAO_2) or arterial oxygen saturation (SaO_2), or higher alveolar carbon dioxide partial pressure ($PACO_2$) (1,6,8,11,12,17,21). Although two recent studies (9,18) did not find significant differences in ventilation or SaO_2 between sick and well subjects at high altitude, the balance of data suggests a relatively greater hypoxemia in AMS-susceptible subjects compared to non-susceptible subjects at high altitude.

Given the degree of ventilatory acclimatization achieved by the MAR group, we would expect such personnel to be less susceptible to AMS. Our results are consistent with this view. Only one subject in the MAR group developed AMS, whereas nine subjects in the LAR group did. On the other hand, given the relatively short duration of high altitude exposure in this study, the approximately 23% incidence of AMS in the LAR group is higher than the literature would suggest (16). It is possible that early development of AMS is common and that previous studies have missed this early emergence of AMS symptoms simply because they did not assess AMS within this timeframe. Over the course of 24 - 49 h exposures to 4,056 m, AMS incidence is approximately 70% in unacclimatized lowlanders (16). Although the low incidence of AMS in the MAR group is predicted, because of the short exposure duration, we cannot discount the possibility that more members of the MAR group would develop AMS had the exposure duration been longer. However, we would predict a lower incidence of AMS in the MAR group compared to the LAR group at any length of high altitude exposure.

CONCLUSIONS

The results of this study support our hypothesis that lowlanders acclimatized to moderate altitudes will maintain a higher level of arterial oxygenation when rapidly ascending to higher altitudes compared to lowlanders residing at low altitudes. These data suggest that personnel residing at ~2,000 m elevation for more than 90 days have

acquired a level of ventilatory acclimatization equivalent to residing at 4,056 m for 5 – 9 days. The results also suggest that measurement of resting SaO₂ at altitudes of 2,438 m or more are predictive of resting SaO₂ at higher altitudes and may be a useful clinical tool for assessing ventilatory acclimatization in a field or operational setting.

Finally, we speculate that given the degree of ventilatory acclimatization achieved by personnel residing at the moderate altitude studied, we would expect such personnel to be less susceptible to high altitude sickness and decrements in cognitive and physical performance during rapid ascent to higher altitudes. Lowlanders who have achieved the level of acclimatization seen in our MAR group usually have complete restoration of cognitive performance and substantial improvements in physical work performance (2,25). However, quantitative assessment of the effects of moderate altitude residence on cognitive and physical work performance will require further studies. Nevertheless, the results of the present study suggest that military personnel residing at moderate altitudes for a period of at least 90 days can be rapidly deployed to higher altitudes of up to 4,056 m with a low probability of developing AMS and experiencing significant performance decrements.

REFERENCES

1. Anholm, J. D., C. S. Houston, and T. M. Hyers. The relationship between acute mountain sickness and pulmonary ventilation at 2835 m (9,300 feet). *Chest* 75: 33-36, 1979.
2. Banderet, L. E. and R. L. Burse. Effects of high terrestrial altitude on military performance. In: *Handbook of Military Psychology*. edited by Gal, R. and D. Mangelsdorff. New York: Wiley & Sons, Ltd., 1991, pp.233-254.
3. Beidleman, B. A., S. R. Muza, P. B. Rock, C. S. Fulco, T. P. Lyons, R. W. Hoyt, and A. Cymerman. Exercise responses after altitude acclimatization are retained during reintroduction to altitude. *Med. Sci. Sports Exerc.* 29: 1588-1595, 1997.
4. Bender, P. R., B. M. Groves, R. E. McCullough, R. G. McCullough, S. Y. Huang, A. J. Hamilton, P. D. Wagner, A. Cymerman, and J. T. Reeves. Oxygen transport to exercising leg in chronic hypoxia. *J. Appl. Physiol.* 65: 2592-2597, 1988.
5. Bisgard, G. E. and H. V. Forster. Ventilatory responses to acute and chronic hypoxia. In: *Handbook of Physiology Section 4: Environmental Physiology*. edited by Fregly, M. J. and C. M. Blatteis. New York: Oxford University Press, 1996, pp.1207-1239.
6. Boycott, A. E. and J. S. Haldane. The effects of low atmospheric pressures on respiration. *J. Physiol (Lond)* 37: 355-377, 1908.
7. Fulco, C. S. and A. Cymerman. Human performance and acute hypoxia. In: *Human Performance Physiology and Environmental Medicine at Terrestrial Extremes*. edited by Pandolf, K. B., M. N. Sawka, and R. R. Gonzalez. Indianapolis: Benchmark, 1988, pp.467-495.
8. Hackett, P. H., D. Rennie, S. E. Hofmeister, R. F. Grover, E. B. Grover, and J. T. Reeves. Fluid retention and relative hypoventilation in acute mountain sickness. *Respiration* 43: 321-329, 1982.
9. Hoefler, M., G.W. Sybrecht and D. Bauer. Hypoxic ventilatory response and associated heart rate change predict the severity of acute mountain sickness. In: *Advances in Experimental Medicine and Biology*. edited by Roach, R. C., Wagner, P. D., and Hackett, P. H. New York, Kluwer Academic / Plenum, 2001, pp. 391-474.
10. Hsia, C. C. W. Mechanisms of disease: respiratory function of hemoglobin. *N. Engl. J. Med.* 338: 239-247, 1998.

11. Kronenberg, R. S., P. Safar, and J. Lee. Pulmonary artery pressure and alveolar gas exchange in man during acclimatization to 12,470 feet. *J. Clin. Invest.* 50: 827-837, 1971.
12. Moore, L. G., G. L. Harrison, R. E. McCullough, R. G. McCullough, A. J. Micco, A. Tucker, J. V. Weil, and J. T. Reeves. Low acute hypoxic ventilatory response and hypoxic depression in acute altitude sickness. *J. Appl. Physiol.* 60: 1407-1412, 1986.
13. Muza, S. R., P. B. Rock, C. S. Fulco, S. Zamudio, B. Braun, A. Cymerman, G. E. Butterfield, and L. G. Moore. Women at altitude: ventilatory acclimatization at 4,300 m. *J. Appl. Physiol.* 91: 1791-1799, 2001.
14. Reeves, J. T., R. E. McCullough, L. G. Moore, A. Cymerman, and J. V. Weil. Sea-level PCO₂ relates to ventilatory acclimatization at 4,300 m. *J. Appl. Physiol.* 75: 1117-1122, 1993.
15. Roach, J. M. and R. B. Schoene. High-altitude pulmonary edema. In: *Medical aspects of harsh environments*. edited by Lounsbury, D. E., R. F. Bellamy, and R. Zajtchuk. Washington, D.C.: Office of the Surgeon General, Borden Institute, 2002, pp.795-820.
16. ROACH, R., J. Stepanek, and P. H. Hackett. Acute mountain sickness and high-altitude cerebral edema. In: *Medical aspects of harsh environments*. edited by Lounsbury, D. E., R. F. Bellamy, and R. Zajtchuk. Washington, D.C.: Office of the Surgeon General, Borden Institute, 2002, pp.765-793.
17. Roach, R. C., E. R. Greene, R. B. Schoene, and P. H. Hackett. Arterial oxygen saturation for prediction of acute mountain sickness. *Aviat. Space. Environ. Med.* 69: 1182-1185, 1998.
18. Roach, R. C., D. Maes, D. Sandoval, R. A. Robergs, M. Icenogle, H. Hinghofer-Szalkay, D. Lium, and J. A. Loepky. Exercise exacerbates acute mountain sickness at simulated high altitude. *J. Appl. Physiol.* 88: 581-585, 2000.
19. Sampson, J. B., A. Cymerman, R. L. Burse, J. T. Maher, and P. B. Rock. Procedures for the measurement of acute mountain sickness. *Aviat. Space Environ. Med.* 54: 1063-1073, 1983.
20. Schoene, R. B., S. Lahiri, P. H. Hackett, R. M. J. Peters, J. S. Milledge, C. J. Pizzo, F. H. Sarnquist, S. J. Boyer, D. J. Graber, K. H. Maret, and J. B. West. Relationship of hypoxic ventilatory response to exercise performance on Mount Everest. *J. Appl. Physiol.* 56(6): 1478-1483, 1984.
21. Sutton, J. R., A. C. Bryan, C. W. Gray, E. S. Horton, A. S. Rebeck, W. Woodley, I. D. Rennie, and C. S. Houston. Pulmonary gas exchange in acute mountain sickness. *Aviat. Space Environ. Med.* 47: 1032-1037, 1976.

22. Weil, J. V. Ventilatory control at high altitude. In: *Handbook of Physiology, Section 3: The Respiratory System, Vol. II. Control of Breathing, Part 2.* edited by Fishman, A. P., N. S. Cherniack, and J. G. Widdicombe. Bethesda, MD: American Physiological Society, 1986, pp.703-727.
23. White, D. P., K. Gleeson, C. K. Pickett, A. M. Rannels, A. Cymerman, and J. V. Weil. Altitude acclimatization: influence on periodic breathing and chemoresponsiveness during sleep. *J. Appl. Physiol.* 63: 401-412, 1987.
24. Wolfel, E. E., B. M. Groves, G. A. Brooks, G. E. Butterfield, R. S. Mazzeo, L. G. Moore, J. R. Sutton, P. R. Bender, T. E. Dahms, and R. E. McCullough. Oxygen transport during steady-state submaximal exercise in chronic hypoxia. *J. Appl. Physiol.* 70: 1129-1136, 1991.
25. Young, A. J. and P. M. Young. Human acclimatization to high terrestrial altitude. In: *Human Performance Physiology and Environmental Medicine at Terrestrial Extremes.* edited by Pandolf, K. B., M. N. Sawka, and R. R. Gonzalez. Indianapolis: Benchmark Press, Inc., 1988, pp.497-543.